News
Boston, USA-based clinical-stage biopharma Odyssey Therapeutics announced the closing of a $213 million Series D financing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback